Biography
Dr. Bahram G. Kermani is an expert in the fields of genomics, computational biology, signal processing, and machine learning. Prior to starting Crystal Genetics, he held various executive and technical positions at Guardant Health, Complete Genomics, Illumina, and Bell Labs (Lucent). Dr. Kermani completed his postdoctoral fellowship at Duke University Medical Center. He received his Ph.D. and M.S. in electrical engineering, and minoring in biomedical engineering from North Carolina State University; and received his B.S. in electronics engineering from Amirkabir University of Technology. Dr. Kermani has several publications in the areas of genomics, biomedical engineering, and electrical engineering, and holds in excess of 47 issued patents in the United States, European Union, and Japan.

Liquid Biopsy Showcase:
Crystal Genetics, Inc.
Crystal Genetics is a genetic testing company, with a primary focus on early detection of cancer using liquid biopsy. Leveraging the powers of single-cell analysis, whole genome sequencing and AI, we target population-level cancer screening applications --all of which demand ultra-high specificity.

Screening Applications For Early Detection Of Cancer
Early detection of cancer using liquid biopsy has recently been en vogue, due to its potential to drastically improve the survival rate of cancer patients, while being minimally invasive. We present a high-specificity detection framework as mandated by screening applications.